JANX Key Statistics, Chart & Performance
The current stock price of JANX is 14.03 USD. In the past month the price decreased by -8.66%. In the past year, price decreased by -65.55%.
JANX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.28 | 388.89B | ||
| AMGN | AMGEN INC | 14.89 | 175.30B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.53 | 116.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 727.27 | 49.00B | ||
| INSM | INSMED INC | N/A | 35.77B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.65B | ||
| INCY | INCYTE CORP | 16.56 | 20.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 20.77B |
Related stock screener links
About JANX
Company Profile
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 74 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Company Info
JANUX THERAPEUTICS INC
10955 Vista Sorrento Parkway, Suite 200
San Diego CALIFORNIA US
CEO: David Campbell
Employees: 103
Phone: 18587514493
JANUX THERAPEUTICS INC / JANX FAQ
What does JANX do?
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 74 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
What is the current price of JANX stock?
The current stock price of JANX is 14.03 USD. The price decreased by -0.92% in the last trading session.
What is the dividend status of JANUX THERAPEUTICS INC?
JANX does not pay a dividend.
What is the ChartMill rating of JANUX THERAPEUTICS INC stock?
JANX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is JANUX THERAPEUTICS INC (JANX) stock traded?
JANX stock is listed on the Nasdaq exchange.
What is JANUX THERAPEUTICS INC worth?
JANUX THERAPEUTICS INC (JANX) has a market capitalization of 843.90M USD. This makes JANX a Small Cap stock.
What is the Short Interest ratio of JANUX THERAPEUTICS INC (JANX) stock?
The outstanding short interest for JANUX THERAPEUTICS INC (JANX) is 13.68% of its float.
JANX Technical Analysis
JANX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JANX. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability.
JANX Financial Highlights
Over the last trailing twelve months JANX reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -43.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.94% | ||
| ROE | -10.43% | ||
| Debt/Equity | 0 |
JANX Forecast & Estimates
26 analysts have analysed JANX and the average price target is 68.08 USD. This implies a price increase of 385.28% is expected in the next year compared to the current price of 14.03.
For the next year, analysts expect an EPS growth of -59.85% and a revenue growth -9.12% for JANX